Table 1 Clinical features of acute respiratory distress syndrome (ARDS) patients
From: Role of endothelial microRNA 155 on capillary leakage in systemic inflammation
Characteristic | All (n = 16) |
|---|---|
Age (y), median (IQR) | 52 (43–66) |
Male (%) | 12 (75) |
Body mass index (kg/m2), median (IQR) | 27.7 (24.4–33.3) |
Septic shock (%) | 9 (56) |
Pneumogenic focus (%) | 7 (78) |
Primary ARDS (%) | 14 (88) |
Diagnosis | |
Pneumonia due to | 14 (88) |
Influenza A | 4 (29) |
Streptococcus pneumononiae | 4 (29) |
Legionella pneumophilia | 1 (7) |
Staphylococcus aureus with septicaemia | 1 (7) |
Unidentified pathogen | 4 (29) |
Pancreatitis with sepsis and secondary ARDS | 1 (6) |
Septic shock of unknown focus with secondary ARDS | 1 (6) |
Laboratory at time of sampling | |
CRP (mg/L), median (IQR) | 252 (134–305) |
Procalcitonin (ng/L), median (IQR) | 7.7 (1.4–29.1) |
Leukocytes (gpt/L), median (IQR) | 8.2 (4.8–19.1) |
Lactate (mmol/L), median (IQR) | 1.6 (1.2–3.2) |
paO2 / FiO2 (mmHg), median (IQR) | 109 (77–132) |
SOFA score at day of sampling (IQR) | 11.5 (8.5–13.0) |
Treatment modalities at time of sampling | |
Invasive ventilation | 16 (100) |
PEEP (mbar), median (IQR) | 14 (12–15) |
Pmax (mbar), median (IQR) | 26 (23–28) |
Extracorporeal membrane oxygenation (%) | 7 (44) |
Renal replacement therapy (%) | 10 (63) |
Vasopressor use (%) | 13 (81) |
Noradrenaline dose (µg/kg/min), median (IQR) | 0.085 (0.02–0.35) |
28-day ICU-mortality (%) | 5 (31) |